Company Overview of MOTUS THERAPEUTICS, INC.
MOTUS THERAPEUTICS, INC., a biopharmaceutical company, develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases. The company’s product candidate, relamorelin, is a potent, ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes, and other GI functional disorders. Its relamorelin is derived from the natural ghrelin sequence that targets the receptor for ghrelin, which is a naturally occurring hormone that plays a critical role in GI motility, digestion, and the absorption of nutrients. MOTUS THERAPEUTICS, INC. was formerly known as Rhythm Pharmaceuticals, Inc. and changed its name to MOTUS THERAPEUTICS, INC. in September 2014...
855 Boylston Street
Boston, MA 02116
Founded in 2008
Key Executives for MOTUS THERAPEUTICS, INC.
Chairman and Chief Executive Officer
Founder and Member of Scientific Advisory Board
Compensation as of Fiscal Year 2016.
MOTUS THERAPEUTICS, INC. Key Developments
Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Apr 4 16
Motus announced the completion of enrollment for a Phase 2b clinical trial assessing the efficacy and safety of relamorelin (RM-131), Motus' ghrelin agonist, for the treatment of gastroparesis in patients with type 1 and type 2 diabetes. Ghrelin is a peptide hormone produced in the stomach that stimulates gastrointestinal (GI) motility. Allergan has an exclusive option to acquire Motus Therapeutics, Inc. upon the completion of this Phase 2b study. The Phase 2b trial is designed to evaluate the effect of relamorelin on signs and symptoms of gastroparesis, GI motility, and safety in patients with diabetic gastroparesis. The randomized, double-blind, placebo-controlled study is evaluating the safety and efficacy of dosing regimens ranging from 10 to 100 mcg administered twice daily over three months. The trial enrolled 396 patients with diabetic gastroparesis at clinical sites in the U.S and Europe.
Rhythm Announces Executives Appointments
Dec 28 15
Rhythm reported that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and McGirr is former Chief Financial Officer of Cubist Pharmaceuticals.
Rhythm Appoints David Meeker, MD, David McGirr to Board of Directors
Dec 16 15
Rhythm announced that the company has appointed David Meeker, MD, and David McGirr to its Board of Directors. Dr. Meeker is President and Chief Executive Officer of Genzyme, and Mr. McGirr is former Chief Financial Officer of Cubist Pharmaceuticals. David Meeker, MD, is President and Chief Executive Officer of Genzyme. David McGirr was a Senior Advisor to the Chief Executive Officer of Cubist Pharmaceuticals until June 2014 and a Senior Vice President and Chief Financial Officer of Cubist from 2002 to 2013.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 27, 2016